HC Wainwright Estimates Surrozen’s Q1 Earnings (NASDAQ:SRZN)
Research analysts at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for Surrozen in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now anticipates ...
Sensus Healthcare’s (SRTS) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Sensus Healthcare (NASDAQ:SRTS – Free Report) in a report released on ...
MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co
Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the ...
Fintel on MSN3d
HC Wainwright & Co. Initiates Coverage of Kairos Pharma (KAPA) with Buy Recommendation
Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...
Fintel on MSN4d
HC Wainwright & Co. Upgrades Sarepta Therapeutics (SRPT)
Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...
Kalkine Media5d
Could HC Wainwright's Appraisal Backfire on Cabaletta Bio?
Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to ...
H.C. Wainwright sees increased uncertainty for Sarepta franchise
H.C. Wainwright sees increased uncertainty for Sarepta’s Elevidys franchise after the European Medicines Agency placed a clinical hold on three drug trials. The clinical hold on ...
H.C. Wainwright Keeps Their Hold Rating on Ryvyl (RVYL)
H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Ryvyl (RVYL – Research Report) today. The company’s shares closed yesterday at ...
Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating
Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.
Investing3d
H.C. Wainwright maintains BiomX stock Buy rating, $21 target
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.